OncoMatch/Clinical Trials/NCT06672575
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Is NCT06672575 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Ivonescimab for glioblastoma.
Treatment: Ivonescimab — The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Disease stage
Grade: 4 (WHO CNS 2021)
Recurrent supratentorial Glioblastoma that has progressed following standard therapy; ... Diagnosis of Glioblastoma IDH-wildtype, WHO Grade 4 consistent with WHO CNS 2021 criteria.
Prior therapy
Must have received: radiation therapy
patients must have previously been treated with radiation with or without temozolomide
Cannot have received: anti-VEGF therapy
History of prior treatment of GB with anti-VEGF ... agents, including monotherapy with either category or combinations thereof.
Cannot have received: anti-PD-1 therapy
History of prior treatment of GB with ... anti-PD-1/PDL-1 agents, including monotherapy with either category or combinations thereof.
Cannot have received: anti-PD-L1 therapy
History of prior treatment of GB with ... anti-PD-1/PDL-1 agents, including monotherapy with either category or combinations thereof.
Cannot have received: interstitial brachytherapy
Has received prior interstitial brachytherapy
Cannot have received: interstitial thermal therapy
Has received prior ... interstitial thermal therapy
Cannot have received: implanted chemotherapy
Has received prior ... implanted chemotherapy
Cannot have received: local injection or convection enhanced delivery
Has received prior ... therapeutics delivered by local injection or convection enhanced deliver
Cannot have received: Gliadel wafer (Gliadel)
Prior treatment with Gliadel ® wafers will be excluded
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; Hemoglobin ≥ 9.0 g/dL
Kidney function
Creatinine clearance (CrCL) ≥ 50 mL/min or eGFR ≥50 mL/min; Urine protein < 2+ or 24-hour urine protein quantification < 1.0 g or Urine protein/Creatinine ratio ≤ 1mg/mg (≤ 113.2mg/mmol)
Liver function
Serum total bilirubin (TBIL) ≤ 1.5 × ULN (≤3 × ULN for Gilbert syndrome); AST and ALT ≤ 2.5 × ULN
Adequate Organ Function, with screening labs performed within 14 days of treatment initiation: ... Hematology ... Kidneys ... Liver ... Coagulation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify